The use of animals in biomedical research is a contentious issue which attracts strong feelings, conflicting views, and considerable media attention. Reconciling the diversity of opinions on this topic is a daunting task, but one which should be tackled.
Most difficult to reconcile is the fundamental difference in views between those who feel that no animal should ever suffer for the benefit of humans, and others who believe that it is necessary to use animals for understanding disease and the development of new medicines, whilst recognising that we have a responsibility to use animals with thought and care for their welfare. A common, "middle-ground" view (which recent opinion polls suggest is shared by many) is a reluctant acceptance of the need to use animals in research, provided that it is likely to lead to advances in medicine, that there are no feasible alternatives, and that the experiments are regulated strictly. Unfortunately, the same surveys reveal a poor public knowledge and understanding of the nature of biomedical research and the strict regulations on animal experiments and their enforcement in the UK.
The UK is widely recognised as operating the most extensive system for regulating animal experiments in the world. Every place, person, project and procedure involving an experiment on regulated animals must be approved at several levels. No experiment can be undertaken if valid alternatives are available (and here valid is an important issue), and for each experiment, a "cost/benefit" analysis must be undertaken. The cost is the suffering of the animals, and the benefit is the likely outcome and its impact on the health and welfare of humans and/or animals. In addition to the national legislation, Local Ethical Review has helped to ensure high standards of animal welfare in the UK. But these regulations should not engender complacency. Scientists must continually seek to improve animal welfare, limit suffering and refine our experimental approaches: we are strongly committed to this principle and our actions confirm this. Here we have much to gain from further interaction and dialogue between scientists and animal-welfare organisations such as FRAME.
Thus, most (but not all) would accept, for example, that the use of a relatively small number of rodents to test a new drug which might be effective against a major disease, would weigh in favour of the studies being undertaken. The analysis is much more difficult when large numbers of animals or higher species are required, and/or the immediate benefit is not so obvious. However, extensive experience tells us that major medical advances take a long time, and often arise from unexpected lines of research, for which the benefits were not readily obvious at the outset.
All of those concerned about animal welfare would like to see the total replacement of animals in research with alternative approaches. This goal is shared by most biomedical researchers, but is not achievable in the foreseeable future. Nevertheless, everyone involved in experiments on animals has a moral and legal obligation to limit their use and most importantly, to minimise their suffering -not only during experiments, but throughout their lives. I am aware of no scientist who wants to use animals in their research; why should they? Apart from the ethical and emotional issues (scientists have feelings about animals just like anyone else, and many have pets), the design, analysis and interpretation of animal experiments is complex, difficult and time-consuming. Experiments on animals are expensive and demand a great deal of time and effort to be spent in obtaining approval, and, of course, some scientists are threatened, abused and attacked for what they do. With all of these hurdles, it is hard to imagine that any scientist sees the use of animals as the "easy option", in preference to viable alternative approaches.
The real problem is to identify valid alternatives. There are, of course, many alternatives to the use of animals that can be, and are, used extensively, such as in vitro experiments on organs, tissues or cells (although most of these require animal tissue), human studies, computer simulation etc. These can provide excellent, complementary approaches that, hopefully one day, will fully replace animals. Unfortunately, we are still some way from this. We cannot yet understand the complexities of the brain, or of the immune system and the way that it interacts with the endocrine system, without in vivo studies. For example, in my own research, studies on brain cells (neurones) in vitro yielded exactly the opposite result to in vivo experiments in rats. The use of imaging in human subjects has led to great advances in understanding normal function and disease states, particularly in the brain, yet imaging still cannot get anywhere close to the cellular level, and there are concerns about radiation doses, and difficulties in imaging some patients (for example, children, the elderly or those with psychiatric disease). It is rarely possible to study humans before they succumb to disease, let alone to test experimental interventions. Post-mortem studies are becoming ever more difficult, with concerns about organ donation, and more people dying at home or in sheltered accommodation (where rapid post mortem examination is difficult), and again we are studying the system long after the event.
Extensive discussion of the justification and validation of animal experiments is not appropriate here, and could take up many issues of ATLA. We need to face the reality, however unfortunate, that virtually no new medical or veterinary drug or surgical advance in the last 25 years has (or probably could have) been discovered, developed or applied generally to clinical or veterinary diseases without some use of animals. The list of advances is long, but includes, for example, effective, new anti-cancer drugs, treatments to regulate hypertension and arteriosclerosis, migraine and gastric ulcers, and the development of vaccines (e.g. for meningitis C), safer "biologicals" such as insulin, Factor VII and growth hormone, new surgical approaches (e.g. coronary bypass) and immunological treatments (e.g. in transplant rejection). Of course, not all new drugs have fully met initial optimistic expectations as products. Some of the "spectacular failures" might have been avoided with further use of animals. The devastating effects of thalidomide provide an excellent example of a drug treatment that, with the use of the rigorous animal testing we have today (required by law), would never have been used in pregnant women. Indeed, the fact that we have not had another similar tragedy is testament to the value of such testing which has identified many compounds with teratogenic effects.
The important goal is to find common ground and to move forward the primary aims of the Three Rs. It is time for scientists to work more closely with animal-welfare organisations such as FRAME to further reduce, refine and replace animal experiments. We need to break down the barriers between scientists and animal-welfare groups, to understand and accept differing views and combine our efforts. We all have much to benefit, but most importantly, future collaboration and constructive dialogue between scientists and animal-welfare groups will offer real benefits to the animals.
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